A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2010

Conditions
G(M2) GangliosideTay-Sachs Disease GangliosideSandhoff Disease Ganglioside
Interventions
DRUG

Pyrimethamine

Pyrimethamine will be given PO once daily for 8 consecutive weeks.

Trial Locations (3)

10016

New York University, School of Medicine, Department of Neurology, New York

44106

University Hospitals of Cleveland, Cleveland

M5G 1X8

Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University Hospitals Cleveland Medical Center

OTHER

collaborator

NYU Langone Health

OTHER

collaborator

The Hospital for Sick Children

OTHER

lead

Exsar Corporation

INDUSTRY